Regorafenib News and Research

RSS
New drug combinations and dosing schedules improve outlook in advanced colon cancer

New drug combinations and dosing schedules improve outlook in advanced colon cancer

Study suggests usefulness of more flexible dose of regorafenib to relieve side-effects in mCRC patients

Study suggests usefulness of more flexible dose of regorafenib to relieve side-effects in mCRC patients

New cell co-culture platform holds promise for future of personalized medicine

New cell co-culture platform holds promise for future of personalized medicine

Deciphera presents Phase 1 clinical results of DCC-2618 in patients with gastrointestinal stromal tumors

Deciphera presents Phase 1 clinical results of DCC-2618 in patients with gastrointestinal stromal tumors

New AASLD guideline focuses on improving diagnosis, treatment of liver cancer and NAFLD

New AASLD guideline focuses on improving diagnosis, treatment of liver cancer and NAFLD

New ESMO guidelines reflect personalized approach for management of metastatic colorectal cancer

New ESMO guidelines reflect personalized approach for management of metastatic colorectal cancer

Regorafenib drug improves survival rates in patients with hepatocellular carcinoma

Regorafenib drug improves survival rates in patients with hepatocellular carcinoma

Bayer-new phase 3 liver cancer data

Bayer-new phase 3 liver cancer data

Fish oil supplements combined with anti-cancer therapy can reduce renal cell carcinoma

Fish oil supplements combined with anti-cancer therapy can reduce renal cell carcinoma

VARI-SU2C Epigenetics Dream Team supports new clinical trial that targets metastatic colorectal cancer

VARI-SU2C Epigenetics Dream Team supports new clinical trial that targets metastatic colorectal cancer

Phase IIIb CONSIGN study confirms benefit of regorafenib in patients with pre-treated mCRC

Phase IIIb CONSIGN study confirms benefit of regorafenib in patients with pre-treated mCRC

ARIAD reports data from Iclusig Phase 2 trial in adult patients with gastrointestinal stromal tumors

ARIAD reports data from Iclusig Phase 2 trial in adult patients with gastrointestinal stromal tumors

Bayer enrolls patients for Phase III trial of Stivarga (regorafenib) tablets in colorectal cancer

Bayer enrolls patients for Phase III trial of Stivarga (regorafenib) tablets in colorectal cancer

New drug combination therapy effectively kills cancer cells

New drug combination therapy effectively kills cancer cells

European Commission approves Stivarga tablets for treatment of patients with mCRC

European Commission approves Stivarga tablets for treatment of patients with mCRC

ARIAD Pharmaceuticals initiates ponatinib Phase 2 trial in adult patients with metastatic GIST

ARIAD Pharmaceuticals initiates ponatinib Phase 2 trial in adult patients with metastatic GIST

Bayer HealthCare to present new data on oncology portfolio at ASCO meeting

Bayer HealthCare to present new data on oncology portfolio at ASCO meeting

Bayer HealthCare: Patient enrollment underway in Phase III trial of Stivarga tablets for treatment of HCC

Bayer HealthCare: Patient enrollment underway in Phase III trial of Stivarga tablets for treatment of HCC

BEAMing technology detects more mutations linked with secondary drug resistance in GIST patients

BEAMing technology detects more mutations linked with secondary drug resistance in GIST patients

Blood test reveals more gene mutations in cancer than traditional tumor biopsy

Blood test reveals more gene mutations in cancer than traditional tumor biopsy